Email this article 
Hide
Show all
Guideline
Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update
Submitted: 08 December 2023 | Published: 30 March 2024
About the author(s)
Tom Boyles, Clinical HIV Research Unit, Helen Joseph Hospital, Johannesburg, South Africa; and Right to Care (NPC) Centurion, Johannesburg, South Africa; and London School of Hygiene and Tropical Medicine, London, United KingdomRebecca H. Berhanu, Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Centre, Nashville, Tennessee, United States
Neliswa Gogela, Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
Hannah Gunter, Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
Tamsin Lovelock, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Services, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
Ndiviwe Mphothulo, Southern African HIV Clinicians Society, Johannesburg, South Africa
Arifa Parker, Unit for Infection Prevention and Control, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa, South Africa; and Division of Infectious Diseases, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
Helena Rabie, Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
Lauren Richards, Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Phumla Sinxadi, Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; and SAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa
Camilla Wattrus, Southern African HIV Clinicians Society, Johannesburg, South Africa
Mahomed-Yunus Moosa, Department of Infectious Diseases, Division of Internal Medicine, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
Abstract
Keywords
Metrics
Total abstract views: 4411Total article views: 19006
Crossref Citations
1. Adequacy of recommendations for adverse event management in national and international treatment guidelines for rifampicin-susceptible tuberculosis: a systematic review
William Burman, Jayne Ellis, Gila Hale, Katherine Hill
eClinicalMedicine vol: 82 first page: 103148 year: 2025
doi: 10.1016/j.eclinm.2025.103148
2. Molecular links between tuberculosis and lung cancer: pathogenesis and therapeutic challenges
Francis Adu-Amankwaah, Suzzana Dickson Buabeng, Isabella Sanette Agyekum, Ndivhuwo Tshililo, Lucinda Baatjies, Bienyameen Baker
Archives of Microbiology vol: 208 issue: 1 year: 2026
doi: 10.1007/s00203-025-04592-w
3. Risk factors for drug-induced liver injury in people with HIV on anti-tuberculosis treatment
Pedro Martínez-Ayala, Moises Salgado-de la Mora, José Antonio Velarde-Ruiz Velasco, Luz Alicia González-Hernández, Fernando Amador-Lara, Guillermo Adrián Alanis-Sánchez, Juan Manuel Aldana-Ledesma, Christian Gerardo Alfaro-Rivera, Sergio Zúñiga-Quiñonez, Vida Verónica Ruiz-Herrera, Paulina Alejandra Sánchez-Álvarez, Jaime Federico Andrade-Villanueva
Enfermedades infecciosas y microbiologia clinica (English ed.) vol: 44 issue: 5 first page: 503041 year: 2026
doi: 10.1016/j.eimce.2026.503041
4. Multi‐Targeted Hepatoprotection: A Combined Extract of Moringa oleifera and Urtica dioica (MU) Combats Drug‐Induced Oxidative Stress and Inflammation via Antioxidant and Molecular Modulatory Effects
Nassima Boutaoui, Nesrine Lariche, Mohamed Zakaria Stiti, Katia Mohand Saidi, Walid Bousbaa, Khellaf Rebbas, Kamel Harrouche, Smail Khelili
Chemistry & Biodiversity vol: 23 issue: 4 year: 2026
doi: 10.1002/cbdv.202502542
5. Genetic polymorphisms and adverse reactions to antituberculosis therapy
Hannah M Gunter, Phuti Choshi, Tafadzwa Chimbetete, Sarah Pedretti, Rannakoe J Lehloenya, Phumla Z Sinxadi, Marylyn D Ritchie, Elizabeth J Phillips, David W Haas, Jonny G Peter
Pharmacogenomics vol: 26 issue: 5-6 first page: 207 year: 2025
doi: 10.1080/14622416.2025.2509479
6. Risk factors associated with anti-tubercular therapy-induced hepatitis in human immunodeficiency virus seropositive and seronegative patients in India
Aneez Jamal KM, Ashutosh Bhosale, Muralidhar Varma, Rajesh Radhakrishnan
International Journal of Risk & Safety in Medicine vol: 37 issue: 1 first page: 131 year: 2026
doi: 10.1177/09246479251401359
7. Risk factors for drug-induced liver injury in people with HIV on anti-tuberculosis treatment
Pedro Martínez-Ayala, Moises Salgado-de la Mora, José Antonio Velarde-Ruiz Velasco, Luz Alicia González-Hernández, Fernando Amador-Lara, Guillermo Adrián Alanis-Sánchez, Juan Manuel Aldana-Ledesma, Christian Gerardo Alfaro-Rivera, Sergio Zúñiga-Quiñonez, Vida Verónica Ruiz-Herrera, Paulina Alejandra Sánchez-Álvarez, Jaime Federico Andrade-Villanueva
Enfermedades Infecciosas y Microbiología Clínica vol: 44 issue: 5 first page: 503041 year: 2026
doi: 10.1016/j.eimc.2025.503041
8. Host Serum Biomarker Signatures in Mycobacteriologically Cured Pulmonary Tuberculosis Patients with Persistent Lung Inflammation on 18F-FDG PET/CT
Bongani Motaung, Solima Sabeel, Mumin Ozturk, Trevor S. Mafu, Muki Shey, Sandra L. Mukasa, Karen Wolmarans, Fareda Jakoet-Bassier, Ashleigh Taylor, Antoneta Mashinyira, Tessa Kotze, Friedrich Thienemann, Reto Guler
Diseases vol: 14 issue: 2 first page: 70 year: 2026
doi: 10.3390/diseases14020070